Pharmaceutical - Novo Nordisk, Research

Filter

Current filters:

Novo NordiskResearch

Popular Filters

1 to 25 of 42 results

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

04-11-2014

A new study has suggested that drugs currently being used to treat diabetes also have the potential to…

liraglutidelixisenatideNeurologicalNovo NordiskPharmaceuticalResearchSanofiUK

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

08-10-2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential…

AdociaBioChaperoneDiabetesFIAspGlobalMarkets & MarketingNovo NordiskPharmaceuticalResearch

Novo Nordisk establishes new obesity research unit in Seattle

Novo Nordisk establishes new obesity research unit in Seattle

26-09-2014

Danish diabetes care giant Novo Nordisk yesterday announced that the company will establish a new obesity…

ManagementMetabolicsNovo NordiskPharmaceuticalResearchSaxendaUSA

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

19-09-2014

The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent…

DenmarkDiabetesEuropeMexicoNovo NordiskPharmaceuticalResearchRyzodegTresibaXultophy

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

Positive new Ph III data with Novo Nordisk’s Xultophy

Positive new Ph III data with Novo Nordisk’s Xultophy

11-08-2014

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchXultophy

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

Significantly greater weight loss versus placebo seen in Ph IIIa study of liraglutide 3mg

16-05-2014

Significant weight loss was demonstrated for Danish insulin giant Novo Nordisk’s diabetes drug liraglutide…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Preventative treatment with NovoEight reduces bleeding in hemophilia A

Preventative treatment with NovoEight reduces bleeding in hemophilia A

12-05-2014

Danish insulin giant Novo Nordisk has announced new Phase III interim data from its guardianT2 trial…

Coagulation systemDenmarkGuardianT2HematologyInsulin giantNovo NordiskNovoEightPharmaceuticalResearchVIII (rFVIII)World Congress

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

03-12-2013

Danish insulin giant Novo Nordisk has presented positive new Phase III data from the investigational…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearch

Data on Novo Nordisk's Victoza further supporting safety presented at expert workshop

14-06-2013

Danish Insulin giant Novo Nordisk (NOV: N) presented data further supporting the safety of Victoza (liraglutide…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial

24-05-2013

Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Positive Ph III results for Novo Nordisk's FIX derivative for hemophilia B

20-05-2013

Danish insulin giant Novo Nordisk (NOV: N) says it has completed paradigm 2, the first Phase III trial…

N9-GPNovo NordiskPharmaceuticalResearch

Emisphere earns $10 million on amended deal with Novo Nordisk

30-04-2013

USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

1 to 25 of 42 results

Back to top